Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Next Previous
Search
Trial Profile

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs A 400-Sichuan Kelun-Biotech Biopharmaceutical (Primary)
  • Indications Brain metastases; Medullary thyroid cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 24 Apr 2025 According to Kelun Pharmaceutical media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 12 Apr 2025 According to Sichuan Kelun Biotech Biopharmaceutical media release, the results from this study were published in the top international medical journal Nature Medicine.
  • 25 Jun 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top